BR0209711A - Composto heterocìclico e seu uso medicinal - Google Patents
Composto heterocìclico e seu uso medicinalInfo
- Publication number
- BR0209711A BR0209711A BR0209711-7A BR0209711A BR0209711A BR 0209711 A BR0209711 A BR 0209711A BR 0209711 A BR0209711 A BR 0209711A BR 0209711 A BR0209711 A BR 0209711A
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- alkyl
- heterocyclic compound
- same
- prophylaxis
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTO HETEROCìCLICO E SEU USO MEDICINAL". O novo composto heterocíclico da presente invenção é um novo composto heterocíclico tendo a fórmula (I) em que R^ 1^ é um H ou C~ 1-6~ alquila, R^ 2^ é H, -CO-C(R^ 4^)=C(R^ 4^)-R^ 5^ em que R^ 4^ é H ou C~ 1-4~ alquila, e R^ 5^ é C~ 4-8~ alquila, C~ 2-a~ alquenila e similares, Y é o grupo que segue em que X é O ou S, R^ 7^ é o mesmo como R^ 4^, R^ 5^ é R^ 10^C(R^ 9^)=C(R^ 9^)- em que R^ 9^ é o mesmo como R^ 4^, R^ 10^ é C~ 3-6~ alquila e similares, R^ 14^ é o mesmo como R^ 4^, e R^ 15^ é arila e similares, Y-(CH~ 2~)~ n~-O-é ligado à posição 6 ou 7 da estrutura de tetraidroisoquinolina; e n é um número inteiro de 1 - 4, ou um sal farmaceuticamente aceitável destes. O composto (I) da presente invenção é útil como um agente hipoglicómico, um agente hipolipidêmico, um melhorador da resistência à insulina, um agente terapêutico de diabetes, um agente terapêutico de complicações diabéticas, um melhorador da tolerância à glicose, um agente antiarteriosclerose, agente antiobesidade, um agente antiinflamatório, um agente para a profilaxia ou tratamento de doenças mediada por PPAR ou um agente para a profilaxia ou tratamento da síndrome X.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001161489 | 2001-05-29 | ||
| PCT/JP2002/005097 WO2002096880A1 (en) | 2001-05-29 | 2002-05-27 | Novel heterocyclic compound and medicinal use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0209711A true BR0209711A (pt) | 2004-11-03 |
Family
ID=19004756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0209711-7A BR0209711A (pt) | 2001-05-29 | 2002-05-27 | Composto heterocìclico e seu uso medicinal |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7557123B2 (pt) |
| EP (1) | EP1403253A4 (pt) |
| JP (1) | JP4279136B2 (pt) |
| KR (2) | KR100898358B1 (pt) |
| CN (1) | CN1242994C (pt) |
| AR (1) | AR036036A1 (pt) |
| AU (1) | AU2002308889B2 (pt) |
| BR (1) | BR0209711A (pt) |
| CA (1) | CA2448634A1 (pt) |
| CO (1) | CO5540342A2 (pt) |
| CZ (1) | CZ20033450A3 (pt) |
| HU (1) | HUP0401862A3 (pt) |
| IL (1) | IL159085A0 (pt) |
| MX (1) | MXPA03010811A (pt) |
| NO (1) | NO326688B1 (pt) |
| NZ (1) | NZ530358A (pt) |
| PL (1) | PL367639A1 (pt) |
| RU (1) | RU2299197C2 (pt) |
| TW (1) | TWI297008B (pt) |
| WO (1) | WO2002096880A1 (pt) |
| YU (1) | YU94003A (pt) |
| ZA (1) | ZA200309757B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ530313A (en) | 2001-05-29 | 2005-06-24 | Kyoto Pharma Ind | Heterocyclic derivatives and medicinal use thereof |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| US7718377B2 (en) | 2003-05-29 | 2010-05-18 | Kyoto Pharmaceutical Industries, Ltd. | Insulin resistance curative and method of screening the same |
| TWI359810B (en) * | 2004-11-04 | 2012-03-11 | Mitsubishi Tanabe Pharma Corp | Carboxylic acid derivative containing thiazole rin |
| US7790745B2 (en) * | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| WO2007058504A1 (en) * | 2005-11-21 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same |
| RU2411936C2 (ru) * | 2009-01-11 | 2011-02-20 | Институт физиологии Коми научного центра Уральского отделения Российской академии наук. Государственное учреждение | Применение 2-морфолино-5-фенил-6н-1,3,4-тиадизин, гидробромида в качестве средства, обладающего гиполипидемическим и гипергликемическим эффектом |
| WO2012033195A1 (ja) * | 2010-09-10 | 2012-03-15 | 京都薬品工業株式会社 | 複素環化合物 |
| CN102807526B (zh) * | 2011-06-21 | 2015-12-02 | 寿光富康制药有限公司 | 组蛋白去乙酰化酶抑制剂ZYJ-D08a及其差向异构体的制备方法与应用 |
| WO2020013116A1 (ja) * | 2018-07-10 | 2020-01-16 | 京都薬品工業株式会社 | Ｐｔｐ－１ｂ阻害剤およびその用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| DE3856378T2 (de) | 1987-09-04 | 2000-05-11 | Beecham Group P.L.C., Brentford | Substituierte Thiazolidindionderivate |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| WO1998000137A1 (en) | 1996-07-01 | 1998-01-08 | Eli Lilly And Company | Hypoglycemic and hypolipidemic compounds |
| ATE277907T1 (de) * | 1996-07-01 | 2004-10-15 | Lilly Co Eli | Blutzuckersenkende und lipidsenkende verbindungen |
| GB9817118D0 (en) | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| CN1215059C (zh) | 1999-12-03 | 2005-08-17 | 京都药品工业株式会社 | 新的杂环化合物及其盐和它们的医药用途 |
| US20020037897A1 (en) * | 2000-08-07 | 2002-03-28 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| NZ530313A (en) * | 2001-05-29 | 2005-06-24 | Kyoto Pharma Ind | Heterocyclic derivatives and medicinal use thereof |
-
2002
- 2002-05-27 PL PL02367639A patent/PL367639A1/xx unknown
- 2002-05-27 EP EP02774070A patent/EP1403253A4/en not_active Withdrawn
- 2002-05-27 US US10/478,862 patent/US7557123B2/en not_active Expired - Fee Related
- 2002-05-27 ZA ZA200309757A patent/ZA200309757B/en unknown
- 2002-05-27 CZ CZ20033450A patent/CZ20033450A3/cs unknown
- 2002-05-27 RU RU2003137574/04A patent/RU2299197C2/ru not_active IP Right Cessation
- 2002-05-27 WO PCT/JP2002/005097 patent/WO2002096880A1/ja not_active Ceased
- 2002-05-27 HU HU0401862A patent/HUP0401862A3/hu unknown
- 2002-05-27 MX MXPA03010811A patent/MXPA03010811A/es active IP Right Grant
- 2002-05-27 AU AU2002308889A patent/AU2002308889B2/en not_active Ceased
- 2002-05-27 KR KR1020087023698A patent/KR100898358B1/ko not_active Expired - Fee Related
- 2002-05-27 IL IL15908502A patent/IL159085A0/xx unknown
- 2002-05-27 JP JP2003500060A patent/JP4279136B2/ja not_active Expired - Fee Related
- 2002-05-27 BR BR0209711-7A patent/BR0209711A/pt not_active IP Right Cessation
- 2002-05-27 CA CA002448634A patent/CA2448634A1/en not_active Abandoned
- 2002-05-27 YU YU94003A patent/YU94003A/sh unknown
- 2002-05-27 NZ NZ530358A patent/NZ530358A/en unknown
- 2002-05-27 KR KR10-2003-7015611A patent/KR20040030647A/ko not_active Withdrawn
- 2002-05-27 CN CNB028109643A patent/CN1242994C/zh not_active Expired - Fee Related
- 2002-05-28 TW TW091111315A patent/TWI297008B/zh active
- 2002-05-29 AR ARP020102002A patent/AR036036A1/es unknown
-
2003
- 2003-11-28 NO NO20035331A patent/NO326688B1/no not_active IP Right Cessation
- 2003-12-29 CO CO03112806A patent/CO5540342A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100898358B1 (ko) | 2009-05-20 |
| NZ530358A (en) | 2005-04-29 |
| NO326688B1 (no) | 2009-01-26 |
| JP4279136B2 (ja) | 2009-06-17 |
| US20040220215A1 (en) | 2004-11-04 |
| US7557123B2 (en) | 2009-07-07 |
| EP1403253A4 (en) | 2005-03-30 |
| KR20040030647A (ko) | 2004-04-09 |
| RU2003137574A (ru) | 2005-05-20 |
| YU94003A (sh) | 2006-08-17 |
| JPWO2002096880A1 (ja) | 2004-09-09 |
| RU2299197C2 (ru) | 2007-05-20 |
| CZ20033450A3 (cs) | 2004-05-12 |
| TWI297008B (en) | 2008-05-21 |
| CO5540342A2 (es) | 2005-07-29 |
| HUP0401862A2 (hu) | 2004-12-28 |
| PL367639A1 (en) | 2005-03-07 |
| HUP0401862A3 (en) | 2009-03-30 |
| AR036036A1 (es) | 2004-08-04 |
| WO2002096880A1 (en) | 2002-12-05 |
| KR20080093076A (ko) | 2008-10-17 |
| NO20035331D0 (no) | 2003-11-28 |
| CN1527819A (zh) | 2004-09-08 |
| CN1242994C (zh) | 2006-02-22 |
| ZA200309757B (en) | 2004-12-22 |
| AU2002308889B2 (en) | 2007-09-06 |
| CA2448634A1 (en) | 2002-12-05 |
| MXPA03010811A (es) | 2004-02-27 |
| IL159085A0 (en) | 2004-05-12 |
| HK1069385A1 (en) | 2005-05-20 |
| EP1403253A1 (en) | 2004-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0016064A (pt) | Compostos heterocìclicos e seus sais e uso medicinal dos mesmos | |
| BRPI0211665B8 (pt) | "composto de pirrol substituído" | |
| KR970027098A (ko) | 프로피오페논 유도체 및 이의 제조 방법 | |
| BR9906813A (pt) | Método para administração de insulina aspb28- humana | |
| BRPI0013667B8 (pt) | derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos e seus intermediários na produção deles | |
| BRPI0407506A (pt) | compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos | |
| EP1698624A4 (en) | phenylpropanoic acid derivatives | |
| BR0205684A (pt) | Compostos cìclicos fundidos e seu uso medicinal | |
| BR9916279A (pt) | Composto, composição farmacêutica, uso de um composto, métodos de tratar ou prevenir doenças do sistema endocrinológico e diabetes melittus não dependente de insulina em um paciente em necessidade deste, e de tratar glicose de resistência prejudicada (ifg) ou tolerância à glicose prejudica (igt) em um paciente em necessida deste, processo para a fabricação de um medicamento particular a ser usado no tratamento ou prevenção de doenças do sistema endocrinológico, e, métodos para preparar os compostos | |
| BR0209711A (pt) | Composto heterocìclico e seu uso medicinal | |
| PT1106178E (pt) | Utilizacao de ibudilast para a preparacao de um medicamento para o tratamento da esclerose multipla | |
| ES528123A0 (es) | Procedimiento de preparacion de derivados de xantina (como divisional de la solicitud de patente de invencion no.515936, solicitada el 24.9.82) | |
| BR0209735A (pt) | Derivados heterocìclicos e uso medicinal destes | |
| BR0016135A (pt) | Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto | |
| KR950007848A (ko) | (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법 | |
| WO2002092072A3 (en) | Drugs for the treatment of the alzheimer disease | |
| BR0314754A (pt) | Agente terapêutico ou profilático para a frequência urinária ou a incontinência urinária ou um seu sal de adição de ácido farmaceuticamente aceitável, método para terapia ou profilaxia para frequência urinária, urgência urinária ou incontinência urinária, uso de um derivado de morfina tendo um grupo heterocìclico contendo nitrogênio ou de um seu sal de adição de ácido farmaceuticamente aceitável, derivado de morfina ou um seu sal de adição de ácido farmaceuticamente aceitável, produto farmacêutico, e, composição farmacêutica | |
| KR970025615A (ko) | 암 전이 억제제 | |
| ATE284697T1 (de) | Pharmazeutische zubereitung auf der basis von rhamnolipid gegen dermatologische erkrankungen | |
| ES2051834T3 (es) | El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad. | |
| BRPI0413758A (pt) | compostos para o tratamento de transtornos metabólicos | |
| BR0210123A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| KR950032191A (ko) | 사이클로헥산 유도체, 이의 제조방법 및 질병을 치료하기 위한 화합물의 용도 | |
| ES2059348T3 (es) | Composicion farmaceutica para el tratamiento de cataratas. | |
| KR890009901A (ko) | 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |